Bladder sensory desensitization decreases urinary urgency

BMC Urology

Volumn 7, Issue , 2007, Pages

  Silva, Carlos ^a   Silva, João ^a   Castro, Helder ^a   Reis, Frederico ^a   Dinis, Paulo ^a   Avelino, António ^a   Cruz, Francisco ^a  

^a University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; RESINIFERATOXIN; SODIUM CHLORIDE; VANILLOID RECEPTOR 1; DITERPENE;

ADULT; AGED; ARTICLE; BLADDER FUNCTION; BLADDER SENSORY DESENSITIZATION; CLINICAL ARTICLE; DESENSITIZATION; DRUG EFFECT; DRUG INSTILLATION; FEMALE; HUMAN; INFORMED CONSENT; MALE; MICTURITION; NERVE FIBER C; OVERACTIVE BLADDER; RATING SCALE; SENSATION; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT OUTCOME; URINARY URGENCY; UROTHELIUM; BLADDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SATISFACTION; URGE INCONTINENCE; URODYNAMICS;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; DITERPENES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; TREATMENT OUTCOME; URINARY BLADDER; URINARY INCONTINENCE, URGE; URINATION; URODYNAMICS;

EID: 34347407675     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-7-9     Document Type: Article

References (36)

1. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. Y Yiangou P Facer A Ford C Brady O Wiseman CJ Fowler P Anand, BJU Int 2001 87 774 779 10.1046/j.1464-410x.2001.02190.x 11412212
2. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. LA Birder AJ Kanai WC de Groat S Kiss ML Nealen NE Burke KE Dineley S Watkins IJ Reynolds MJ Caterina, Proc Natl Acad Sci USA 2001 98 13396 13401 11606761 10.1073/pnas.231243698
3. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. A Apostolidis CM Brady Y Yiangou J Davis CJ Fowler P Anand, Urology 2005 65 400 405 10.1016/j.urology.2004.10.007 15708075
4. Topography of the vanilloid receptorin the human bladder: more than just the nerve fibers. D Ost T Roskams F Van der Aa D de Ridder, J Urol 2002 168 293 297 10.1016/S0022-5347(05)64910-5 12050559
5. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 (VR1) and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity (NDO) following intravesical resiniferatoxin treatment. CM Brady A Apostolidis M Harper Y Yiangou A Beckett TS Jacques A Freeman F Scaravilli CJ Fowler P Anand, BJU Int 2004 93 770 776 10.1111/j.1464-410X.2003. 04722.x 15049988
6. Peptide immunoreactivity and ultrastructure of rat urinary bladder nerve fibers after topical desensitization by capsaicin or resiniferatoxin. A Avelino F Cruz, Autonomic Neuroscience: Basic and clinical 2000 86 1-2 37 46 10.1016/S1566-0702(00)00204-6
7. Intravesical resiniferatoxin desensitizes rat bladder sensory fibers without causing intense noxious excitation. A c-fos study. A Avelino F Cruz A Coimbra, Eur J Pharmacol 1999 378 17 22 10.1016/S0014-2999(99)00451-3 10478560
8. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. D Irwin I Milsom S Hunskaar K Reilly Z Kopp S Herschorn K Coyne C Kelleher C Hampel W Artibani P Abrams, Eur Urol 2006 50 1306 1315 10.1016/j.eururo.2006.09. 019 17049716
9. Efectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. P Herbison J Hay-Smith G Ellis K Moore, BMJ 2003 326 841 844 12702614 10.1136/bmj.326.7394.841
10. Current and future pharmacological treatment for overactive bladder. N Yoshimura MB Chancellor, J Urol 2002 168 1897 1913 10.1016/S0022-5347(05)64261-9 12394674
11. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. A Avelino F Cruz, Naunyn Schmiedeberg's Arch Pharmacol 2006 373 4 287 299 10.1007/s00210-006-0073-2
12. Supression of bladder hyperrelexia by intravesical resiniferatoxin. F Cruz M Guimar̃es C Silva M Reis, Lancet 1997 350 9078 640 641 10.1016/S0140-6736(05)63330-2 9288055
13. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. M Lazzeri P Beneforti D Turini, J Urol 1997 158 2093 2096 10.1016/S0022-5347(01)68164-3 9366319
14. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. C Silva MJ Ribeiro F Cruz, J Urol 2002 168 575 579 10.1016/S0022-5347(05)64683-6 12131313
15. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. CM Brady A Apostolidis Y Yiangou PA Baecker AP Ford A Freeman TS Jacques CJ Fowler P Anand, Eur Urol 2004 46 247 253 10.1016/j.eururo.2003.12.017 15245821
16. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. C Silva J Silva MJ Ribeiro A Avelino F Cruz, Eur Urol 2005 48 650 655 10.1016/j.eururo.2005.04.012 15961217
17. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. A Giannantoni SM Di Stasi RL Stephen V Bini E Costantini M Porena, J Urol 2004 172 240 243 10.1097/01.ju.0000132152.53532.5d 15201783
18. Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. HC Kuo HT Liu WC Yang, J Urol 2006 176 641 645 10.1016/j.juro.2006.03.087 16813911
19. Effect of intravesical resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. A Apostolidis GE Gonzales CJ Fowler, Eur Urol 2006 50 1299 1305 10.1016/j.eururo.2006.04.006 16697519
20. The effect of bladder sensory input modulation on urgency: data from a placebo controlled trial with intravesical resiniferatoxin [abstract]. C Silva J Silva H Castro F Reis P Dinis A Avelino F Cruz, Eur Urol 2006 5 suppl 2 222
21. Using the circumstances of symptoms experience to assess the severity of urgency in the overactive bladder. M Ghei J Malone-Lee, J Urol 2005 174 972 976 10.1097/01.ju.0000177477.83991.88 16094017
22. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. A Nixon S Colman L Sabounjian B Sandage UE Schwiderski DR Staskin N Zinner, J Urol 2005 174 604 607 10.1097/01.ju.0000165461.38088.7b 16006914
23. Validation of the Urgency Perception Scale. L Cardozo KS Coyne E Versi, BJU Int 2005 95 591 596 10.1111/j.1464-410X.2005.05345.x 15705086
24. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. L Brubaker C Chapple KS Coyne Z Kopp, Urology 2006 68 2 suppl 3 8 10.1016/j.urology.2006.05.045 16908335
25. Vanilloid receptors: new insights enhance potential as therapeutic target. A Szallasi PM Blumberg, Pain 1996 68 195 208 10.1016/S0304-3959(96) 03202-2 9121806
26. The capsaicin receptor: a heat-activated ion channel in the pain pathway. MJ Caterina MA Schumacher M Tominaga TA Rosen JD Levine D Julius, Nature 1997 389 816 824 10.1038/39807 9349813
27. The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. L Liu KJ Mansfield I Kristiana KJ Vaux RJ Millard E Burcher, Neurourol Urodyn 2007 26 3 433 438 doi:10.1002.nau.20326 10.1002/nau.20326 17016800
28. Treatment-resistant detrusor overactivity - underlying pharmacologyand potential mechanisms. KE Andersson, Int J Clin Pract 2006 60 suppl 151 8 16 10.1111/j.1742-1241.2006.01184.x
29. Functional properties of TRPV1 expressed in human urothelial cells [abstract]. A Charrua A Avelino I Nagy F Cruz, Neurourol Urodyn 2006 25 558
30. Increased nerve growth factor in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. EM Lowe P Anand G Terenghi RE Williams-Chestnut DV Sinicropi JL Osborne, Br J Urol 1997 79 572 577 9126085
31. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. YC Chuang MO Fraser Y Yu MB Chancellor WC de Groat N Yoshimura, J Urol 2001 165 975 979 10.1016/S0022-5347(05)66587-1 11176525
32. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. JC Kim EY Park SI Seo YH Park T-K Hwang, J Urol 2006 175 1773 1776 10.1016/S0022-5347(05)00992-4 16600756
33. Altered Urinary bladder function in mice lacking the vanilloid receptor TRPV1. LA Birder Y Nakamura S Kiss ML Nealen S Barrick AJ Kanai E Wang G Ruiz WC de Groat G Apodaca S Watkins MJ Caterina, Nat Neurosci 2002 5 856 860 10.1038/nn902 12161756
34. Urinary bladder hyporreflexia and reduced pain-related behaviour in P2X3-deficient mice. DA Cockayne SG Hamilton QM Zhu PM Dunn Y Zhong S Novakovic AB Malmberg G Cain A Berson L Kassotakis L Hedley WG Lachnit G Burnstock SB McMahon APDW Ford, Nature 2000 407 1011 1015 10.1038/35039519 11069181
35. Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. M Trevisani D Smart MJ Gunthorpe M Tognetto M Barbieri B Campi S Amadesi J Gray JC Jerman SJ Brough D Owen GD Smith AD Randall S Harrison A Bianchi JB Davis P Geppetti, Nat Neurosci 2002 5 546 551 10.1038/nn852 11992116
36. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. JHS van Leeuwen R Castro M Busse B Bemelmans, Eur Urol 2006 50 440 453 10.1016/j.eururo.2006.05.014 16753253